Understand the source comparison
Ulcer Healing Peptides 2026 Update: Compound Comparison
BPC-157 VEGF upregulation, FAK-paxillin activation, angiogenesis <5% (cleaved by pepsin) Phase II trials, no FDA approval 200–500 μg daily subcutaneous Strongest preclinical data for ulcer repair; limited large-scale human trials Thymosin β4 Actin sequestratio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, FAK-paxillin activation, angiogenesis
- <5% (cleaved by pepsin)
- Phase II trials, no FDA approval
- 200–500 μg daily subcutaneous
- Strongest preclinical data for ulcer repair; limited large-scale human trials
- Thymosin β4
- Actin sequestration, epithelial migration, wound contraction
- <3% (high MW degradation)
- Phase II completed, Phase III ongoing
- 1.6–6.4 mg twice weekly subcutaneous
- Well-tolerated with NIH-backed research; gastric-specific data emerging
- KPV
- NF-κB inhibition, cytokine suppression (IL-6, TNF-α)
- 8–12% (tripeptide survives transit)
- Phase II inflammatory conditions
- 500 μg–2 mg daily oral or subcutaneous
- Symptom control demonstrated; accelerated healing not yet proven in humans
- Collagen peptides
- Proline/glycine substrate for ECM synthesis
- 15–20% (low MW fragments)
- Multiple RCTs in dermal/joint repair
- 10–20 g daily oral
- Supports connective tissue synthesis; indirect ulcer benefit through collagen availability